Home

Insulet Corporation - Common Stock (PODD)

320.91
+0.00 (0.00%)
NASDAQ · Last Trade: Oct 27th, 8:54 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
1 Safe-and-Steady Stock to Own for Decades and 2 We Brush Off
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Via StockStory · October 27, 2025
INSULET CORP (NASDAQ:PODD): A Prime Candidate for Affordable Growth Investingchartmill.com
Insulet (PODD) is a GARP stock with strong revenue & earnings growth, solid profitability, and a reasonable valuation relative to its industry peers.
Via Chartmill · October 25, 2025
Here's How Much You Would Have Made Owning Insulet Stock In The Last 10 Yearsbenzinga.com
Via Benzinga · October 21, 2025
Louis Navellier's Growth Strategy Highlights Insulet Corp (NASDAQ:PODD)chartmill.com
Discover how Louis Navellier's growth stock strategy identified Insulet Corp (PODD), a leader in innovative insulin delivery with strong earnings and sales growth.
Via Chartmill · October 20, 2025
Discover which S&P500 stocks are making waves on Thursday.chartmill.com
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Thursday.
Via Chartmill · October 9, 2025
Price Over Earnings Overview: Insuletbenzinga.com
Via Benzinga · September 30, 2025
What's going on in today's session: S&P500 gap up and gap down stockschartmill.com
Let's have a look at the S&P500 gap up and gap down stocks in today's session.
Via Chartmill · October 1, 2025
Here's How Much $100 Invested In Insulet 15 Years Ago Would Be Worth Todaybenzinga.com
Insulet (NASDAQ: PODD) has outperformed the market over the past 15 years by 10.02% on an annualized basis producing an average annual return of 22.35%. Currently, Insulet has a market capitalization of $21.87 billion.
Via Benzinga · September 29, 2025
A Glimpse Into The Expert Outlook On Insulet Through 6 Analystsbenzinga.com
6 analysts have shared their evaluations of Insulet (NASDAQ: PODD) during the recent three months, expressing a mix of bullish and bearish perspectives.
Via Benzinga · September 29, 2025
Insulet Corp (NASDAQ:PODD): An Affordable Growth Stock with Strong Profitabilitychartmill.com
Insulet Corp (PODD) exemplifies affordable growth with strong revenue & EPS expansion, high profitability, and a valuation justified by its industry-leading potential.
Via Chartmill · September 27, 2025
Align Technology, ResMed, Insulet, Envista, and Dentsply Sirona Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after the U.S. Commerce Department initiated a national security investigation into medical equipment and devices, raising concerns about potential tariffs. 
Via StockStory · September 25, 2025
Here's How Much $100 Invested In Insulet 10 Years Ago Would Be Worth Todaybenzinga.com
Via Benzinga · September 19, 2025
Why Insulet (PODD) Shares Are Falling Today
Shares of insulin delivery company Insulet Corporation (NASDAQ:PODD) fell 4.3% in the morning session after the company announced a change in its chief financial officer, a move that appeared to overshadow an otherwise positive update to its sales forecast. 
Via StockStory · September 17, 2025
Tech Stocks Slip, Small Caps Soar Ahead Of Fed Rate Decision: What's Moving Markets Wednesday?benzinga.com
Small-cap and blue-chip stocks advanced in Wednesday morning trading on Wall Street, while technology names lagged and the S&P 500 hovered near record levels as investors braced for the Federal Reserve's interest rate decision.
Via Benzinga · September 17, 2025
Top S&P500 movers in Wednesday's sessionchartmill.com
Curious about the S&P500 stocks that are in motion on Wednesday? Join us as we explore the top movers within the S&P500 index during today's session.
Via Chartmill · September 17, 2025
Gapping S&P500 stocks in Wednesday's sessionchartmill.com
Let's have a look at the S&P500 gap up and gap down stocks in today's session.
Via Chartmill · September 17, 2025
3 Reasons Investors Love Insulet (PODD)
Insulet has had an impressive run over the past six months as its shares have beaten the S&P 500 by 18%. The stock now trades at $337, marking a 35.7% gain. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
Via StockStory · September 12, 2025
ResMed, Insulet, Lantheus, Inspire Medical Systems, and Evolent Health Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after markets pulled back, reversing early gains, as investor sentiment remained cautious despite a softer-than-expected inflation reading. 
Via StockStory · September 10, 2025
Which S&P500 stocks are moving on Wednesday?chartmill.com
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Wednesday.
Via Chartmill · September 10, 2025
These S&P500 stocks are gapping in today's sessionchartmill.com
Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Wednesday. Discover the gap up and gap down stocks in the S&P500 index.
Via Chartmill · September 10, 2025
Insulet Corp (NASDAQ:PODD) Combines Technical Strength and Fundamental Momentum for High-Growth Potentialchartmill.com
Insulet Corp (PODD) combines strong technical uptrends with accelerating earnings and revenue growth, making it a top high-growth momentum stock.
Via Chartmill · September 10, 2025
3 S&P 500 Stocks to Target This Week
The S&P 500 (^GSPC) is packed with companies that have built dominant market positions, making it a core index for investors. A select few continue to innovate and expand, setting themselves up for long-term success.
Via StockStory · September 9, 2025
Assessing Insulet: Insights From 6 Financial Analystsbenzinga.com
Via Benzinga · September 8, 2025
$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Todaybenzinga.com
Via Benzinga · September 3, 2025
2 Mid-Cap Stocks Worth Your Attention and 1 We Ignore
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.
Via StockStory · September 1, 2025